<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378844</url>
  </required_header>
  <id_info>
    <org_study_id>GM-11</org_study_id>
    <nct_id>NCT02378844</nct_id>
  </id_info>
  <brief_title>A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic Migraine</brief_title>
  <official_title>A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of gammaCore®, a Non-invasive Vagal Nerve Stimulator (nVNS), for Prevention of Episodic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ElectroCore INC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ElectroCore INC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, double-blind, randomized, sham-controlled, multicentre investigation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period will begin with a four week run-in period, during which there is no
      investigational treatment. The purpose of the run-in period will be observation for baseline
      comparison.

      The run-in period will be, followed by a 12 week randomized period when the subjects will be
      randomized (1:1) to either active treatment or sham (inactive) treatment.

      The randomized period will be followed by a 24 week open label period, where the subjects in
      the sham treatment group will switch in treatment assignment and receive a gammaCore®-R and
      the gammaCore®-R will continue to receive an active treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">August 29, 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Number of Migraine Days</measure>
    <time_frame>last 4 weeks of the randomized/controlled period compared to the subject's own 4-week run-in period.</time_frame>
    <description>Change in number of migraine days (as reported in subject diary), comparing the 4 week run-in period to the last 4 weeks in the randomized period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 50% Responder Rate</measure>
    <time_frame>The last four weeks in the randomization period compared to the four week run-in period.</time_frame>
    <description>The number of subjects with a reduction of 50% or more in number of migraine days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Number of Headache Days</measure>
    <time_frame>The last four weeks in the randomization period compared to the four week run-in period.</time_frame>
    <description>The mean change in number of headache days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Acute Medication Days</measure>
    <time_frame>The last four weeks in the randomization period compared to the four week run-in period.</time_frame>
    <description>The mean change in number of acute medication days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Headache Disability Using Headache Impact Test-6</measure>
    <time_frame>From four week run-in period to last four weeks in the randomization period</time_frame>
    <description>Change in headache disability from the 4 week run-in period to the last 4 weeks of the randomized period as measured using the Headache Impact Test-6 (HIT-6). The HIT-6 measures the impact if a subject's headaches on their ability to function at work, at home and in social situations. Subjects are presented with 6 questions about ability to function and normal daily life and for each question they rate the impact of their headaches as 'never' (6 points) or 'rarely' (9 points) or 'sometimes' (10 points) or 'very often' (11 points) or 'always' (13 points). Minimum score = 36, maximum score = 78. A higher score indicates more impact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period</measure>
    <time_frame>3 months - end of run-in period to end of randomized period</time_frame>
    <description>Migraine Disability Assessment (MIDAS) score from the end of run-in period to the end of randomized period. The MIDAS assessment measures the effect of headaches on a subject's daily functioning. It takes into account the past 3 months and is comprised of five questions. A lower score indicated less disability, a higher score indicates more disability. The scores are graded:
0-5, MIDAS Grade I, little disability 6-10, MIDAS Grade II, mild disability 11 to 20 MIDAS Grade III, moderate disability 21+ MIDAS Grade IV, severe disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L)</measure>
    <time_frame>From four week run-in period to last four weeks in the randomization period</time_frame>
    <description>The descriptive system comprises five dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels (5L): no problems (1) , slight problems (2), moderate problems (3), severe problems (4) and extreme problems (5).
Minimum score is 5 (no problems) and maximum score is 25 (extreme problems)
An overall health question is asked using a visual analogue scale(VAS) from 0-100 where 0 is bad health and 100 good health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Migraine Days in the Open Label Period (Adjusted ANCOVA)</measure>
    <time_frame>The 6 month open-label period compared to the four week run-in period</time_frame>
    <description>Change in number of migraine days (as reported in subject diary) during the 6 month open label period compared to the baseline run-in period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>up to Week 36</time_frame>
    <description>Adverse Effects were collected for all subjects for the duration of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Headache Days in the Open Label Period</measure>
    <time_frame>The 6 month open-label period compared to the four week run-in period</time_frame>
    <description>The mean change in number of headache days (as reported in the subject diary) during the open label period compared to the base-line run-in period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">477</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>gammaCore®-R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gammaCore®-R Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>gammaCore®-R</intervention_name>
    <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
    <arm_group_label>gammaCore®-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>gammaCore®-R Sham</intervention_name>
    <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
    <arm_group_label>gammaCore®-R Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is between the ages of 18 and 75 years.

          2. Has been previously diagnosed with migraine (with or without aura) in accordance with
             the International Classification of Headache Disorders (ICHD)-3 Beta Classification
             criteria.

          3. Experience between 5 and 12 migraine days per month (over the last 4 months) with at
             least 2 of the migraines lasting more than 4 hours.

          4. Has age of onset of migraine less than 50 years old.

          5. Agrees not to use any migraine prevention treatments (including Botox injections)
             and/or medications (exclusive of medications taken for acute relief of migraine
             symptoms).

          6. Agrees to refrain from initiating or changing the type, dosage or frequency of any
             prophylactic medications for indications other than migraine that in the opinion of
             the clinician may interfere with the study objectives (e.g. antidepressant, anti
             convulsant, beta blockers, etc.).

          7. Agrees to use the gammaCore®-R device as intended, follow all of the requirements of
             the study including follow-up visit requirements, record required study data in the
             subject dairy, and other self-assessment questionnaires.

          8. Is able to provide written Informed Consent.

        Exclusion Criteria:

          1. Has a concomitant medical condition that will require oral or injectable steroids
             during the study.

          2. Has a history of any intracranial aneurysm, intracranial haemorrhage, brain tumour or
             significant head trauma.

          3. Has a structural abnormality at the gammaCore®-R treatment site (e.g lymphadenopathy
             previous surgery or abnormal anatomy).

          4. Has pain at the gammaCore®-R treatment site (e.g.dysesthesia, neuralgia and/or
             cervicalgia).

          5. Has other significant pain problem (e.g.cancer pain, fibromyalgia or other head or
             facial disorder) that in the opinion of the investigator may confound the study
             assessments

          6. Has know or suspected severe cardiac disease(e.g. symptomatic coronary artery disease,
             prior myocardial infarction, congestive heart failure (CHF)).

          7. Has known or suspected severe cerebrovascular disease, (e.g. prior stroke or transient
             ischemic attack, symptomatic carotid artery disease, prior carotid endarterectomy or
             other vascular neck surgery).

          8. Has an abnormal baseline Electrocardiogram (ECG) e.g. second and third degree heart
             block, prolonged QT interval, atrial fibrillation, atrial flutter, history of
             ventricular tachycardia or ventricular fibrillation, or clinically significant
             premature ventricular contraction).

          9. Has had a cervical vagotomy.

         10. Has uncontrolled high blood pressure (systolic &gt;160 diastolic &gt; 100 after 3 repeated
             measurements within 24 hours).

         11. Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac
             pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal
             stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion
             stimulator or Occipital nerve stimulator).

         12. Has been implanted with metal cervical spine hardware or has a metallic implant near
             the gammaCore®-R stimulation site.

         13. Has a known history of suspicion of secondary headache.

         14. Has a history of syncope (within the last five years).

         15. Has a history of seizures (within the last five years).

         16. Has a known or suspicion of substance abuse or addiction (within the last 5 years).

         17. Is using marijuana (including medical marijuana) for any indications, more than twice
             a month.

         18. Currently takes simple analgesics or non-steroidal anti-inflammatory drugs (NSAIDs)
             greater than 15 days per month or triptans, ergots or combined analgesics greater than
             10 days per month for headaches or other body pain.

         19. Currently takes prescription opioids greater than 2 days per month for headaches or
             body pain.

         20. Has taken medications for migraine prophylaxis in the previous 30 days.

         21. Has previous diagnosis of medication overuse headache (MoH) , which has reverted to
             episodic migraine within the last 6 months.

         22. Meets the ICHD-3 Beta Classification criteria for chronic migraine (&gt; 15 headache days
             per month).

         23. Has failed an adequate trial (two months or greater) of at least 3 classes of a drug
             therapy for the prophylaxis of migraine .

         24. Has had surgery for migraine prevention.

         25. Has undergone nerve block (occipital or other) in the head or neck within the last 2
             months.

         26. Has received Botox injections within the last 6 months.

         27. Is pregnant or thinking of becoming pregnant during the study period, or of
             childbearing years and is unwilling to use and accepted form of birth control.

         28. Is participating in any other therapeutic clinical investigation or has participated
             in a clinical trial in the preceding 30 days.

         29. Belongs to a vulnerable population or has any condition such that his or her ability
             to provide informed consent, comply with the follow-up requirements, or provide self-
             assessments is compromised (e.g. homeless, developmentally disabled and prisoner).

         30. Is a relative of or an employee of the investigator or the clinical study site.

         31. Has psychiatric or cognitive disorder and/or behavioural problems which in the opinion
             of the clinician may interfere with the study.

         32. Has previously used the gammaCore® device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Christoph Diener, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universtätsklinikum Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurology Department, University of Liège</name>
      <address>
        <city>Liège</city>
        <zip>BE-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik und Poliklinik, Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie, Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTC, University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Migräne- und Kopfschmertzklinik Königstein</name>
      <address>
        <city>Königstein</city>
        <zip>D-61462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie, Ludwig-Maximilliams-Universität, Klinikum Grosshadern</name>
      <address>
        <city>München</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Neurologie und Epileptologie, Hertie-Institut für Klinische Hirnforschung</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DKD HELIOS Klinik Wiesbaden</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Athens Naval Hospital</name>
      <address>
        <city>Athens</city>
        <zip>GR-11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Leiden University Center</name>
      <address>
        <city>Leiden</city>
        <zip>NL-2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandvika Nevrosenter AS</name>
      <address>
        <city>Sandvika</city>
        <zip>N-1300</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Unit, University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>ES-31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurologia, Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>ES-46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basildon University Hospital</name>
      <address>
        <city>Basildon</city>
        <state>Essex</state>
        <zip>SS16 5NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Clinical and Expermental Medicine</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, The Southern Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, The Walton Center</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 9PJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <results_first_submitted>July 16, 2018</results_first_submitted>
  <results_first_submitted_qc>July 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2019</results_first_posted>
  <last_update_submitted>July 14, 2019</last_update_submitted>
  <last_update_submitted_qc>July 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Results from the whole study will published but not individual participant data.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02378844/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02378844/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>gammaCore®-R</title>
          <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
        </group>
        <group group_id="P2">
          <title>gammaCore®-R Sham</title>
          <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
        </group>
        <group group_id="P3">
          <title>Not Randomized</title>
          <description>Subjects that were screen failures and were not randomized</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Run-in Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="172"/>
                <participants group_id="P3" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="136"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Randomized Period (Double Blind)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized population, Intention to Treat (ITT)</population>
      <group_list>
        <group group_id="B1">
          <title>gammaCore®-R</title>
          <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
        </group>
        <group group_id="B2">
          <title>gammaCore®-R Sham</title>
          <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="165"/>
            <count group_id="B2" value="167"/>
            <count group_id="B3" value="332"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Year of inclusion minus date of birth</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="11.11"/>
                    <measurement group_id="B2" value="41.4" spread="12.26"/>
                    <measurement group_id="B3" value="42.4" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Sex, male or female, reported at time of inclusion in study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnicity recorded at time of inclusion into study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Numbers of enrolled subjects per country</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Number of Migraine Days</title>
        <description>Change in number of migraine days (as reported in subject diary), comparing the 4 week run-in period to the last 4 weeks in the randomized period.</description>
        <time_frame>last 4 weeks of the randomized/controlled period compared to the subject's own 4-week run-in period.</time_frame>
        <population>Randomized population, Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number of Migraine Days</title>
          <description>Change in number of migraine days (as reported in subject diary), comparing the 4 week run-in period to the last 4 weeks in the randomized period.</description>
          <population>Randomized population, Intention to Treat (ITT)</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.98" spread="3.031"/>
                    <measurement group_id="O2" value="-1.53" spread="3.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 50% Responder Rate</title>
        <description>The number of subjects with a reduction of 50% or more in number of migraine days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.</description>
        <time_frame>The last four weeks in the randomization period compared to the four week run-in period.</time_frame>
        <population>Randomized population, Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 50% Responder Rate</title>
          <description>The number of subjects with a reduction of 50% or more in number of migraine days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.</description>
          <population>Randomized population, Intention to Treat (ITT)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Number of Headache Days</title>
        <description>The mean change in number of headache days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.</description>
        <time_frame>The last four weeks in the randomization period compared to the four week run-in period.</time_frame>
        <population>Randomized population, Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Number of Headache Days</title>
          <description>The mean change in number of headache days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.</description>
          <population>Randomized population, Intention to Treat (ITT)</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="3.623"/>
                    <measurement group_id="O2" value="-1.72" spread="3.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Acute Medication Days</title>
        <description>The mean change in number of acute medication days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period</description>
        <time_frame>The last four weeks in the randomization period compared to the four week run-in period.</time_frame>
        <population>Randomized population, Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Acute Medication Days</title>
          <description>The mean change in number of acute medication days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period</description>
          <population>Randomized population, Intention to Treat (ITT)</population>
          <units>acute medication days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="3.310"/>
                    <measurement group_id="O2" value="-1.02" spread="3.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Headache Disability Using Headache Impact Test-6</title>
        <description>Change in headache disability from the 4 week run-in period to the last 4 weeks of the randomized period as measured using the Headache Impact Test-6 (HIT-6). The HIT-6 measures the impact if a subject's headaches on their ability to function at work, at home and in social situations. Subjects are presented with 6 questions about ability to function and normal daily life and for each question they rate the impact of their headaches as 'never' (6 points) or 'rarely' (9 points) or 'sometimes' (10 points) or 'very often' (11 points) or 'always' (13 points). Minimum score = 36, maximum score = 78. A higher score indicates more impact.</description>
        <time_frame>From four week run-in period to last four weeks in the randomization period</time_frame>
        <population>Randomized population, Intention to Treat (ITT) In the active group 23 subjects had missing data, in the sham group 32 subjects had missing data at the end of the randomized period</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Headache Disability Using Headache Impact Test-6</title>
          <description>Change in headache disability from the 4 week run-in period to the last 4 weeks of the randomized period as measured using the Headache Impact Test-6 (HIT-6). The HIT-6 measures the impact if a subject's headaches on their ability to function at work, at home and in social situations. Subjects are presented with 6 questions about ability to function and normal daily life and for each question they rate the impact of their headaches as 'never' (6 points) or 'rarely' (9 points) or 'sometimes' (10 points) or 'very often' (11 points) or 'always' (13 points). Minimum score = 36, maximum score = 78. A higher score indicates more impact.</description>
          <population>Randomized population, Intention to Treat (ITT) In the active group 23 subjects had missing data, in the sham group 32 subjects had missing data at the end of the randomized period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HIT-6 score Run-in perio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.442" lower_limit="49" upper_limit="74"/>
                    <measurement group_id="O2" value="64.263" lower_limit="44" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIT-6 score end of Randomized period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.234" lower_limit="42" upper_limit="76"/>
                    <measurement group_id="O2" value="60.992" lower_limit="40" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period</title>
        <description>Migraine Disability Assessment (MIDAS) score from the end of run-in period to the end of randomized period. The MIDAS assessment measures the effect of headaches on a subject's daily functioning. It takes into account the past 3 months and is comprised of five questions. A lower score indicated less disability, a higher score indicates more disability. The scores are graded:
0-5, MIDAS Grade I, little disability 6-10, MIDAS Grade II, mild disability 11 to 20 MIDAS Grade III, moderate disability 21+ MIDAS Grade IV, severe disability</description>
        <time_frame>3 months - end of run-in period to end of randomized period</time_frame>
        <population>Randomized population, Intention to Treat (ITT) At randomisation (visit 2) subject numbers are 165 gammaCore-R and 167 gammaCore-R Sham.
At visit 6 the numbers are lower due to early subject discontinuation: 141 gammaCore-R and 132 gammaCore-R Sham</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period</title>
          <description>Migraine Disability Assessment (MIDAS) score from the end of run-in period to the end of randomized period. The MIDAS assessment measures the effect of headaches on a subject's daily functioning. It takes into account the past 3 months and is comprised of five questions. A lower score indicated less disability, a higher score indicates more disability. The scores are graded:
0-5, MIDAS Grade I, little disability 6-10, MIDAS Grade II, mild disability 11 to 20 MIDAS Grade III, moderate disability 21+ MIDAS Grade IV, severe disability</description>
          <population>Randomized population, Intention to Treat (ITT) At randomisation (visit 2) subject numbers are 165 gammaCore-R and 167 gammaCore-R Sham.
At visit 6 the numbers are lower due to early subject discontinuation: 141 gammaCore-R and 132 gammaCore-R Sham</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 of Randomized Period (Visit 2) Grade I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 of Randomized Period (Visit 2) Grade II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 of Randomized Period (Visit 2) Grade III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 of Randomized Period (Visit 2) Grade IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Visit 6) Grade I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Visit 6) Grade II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Visit 6) Grade III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Visit 6) Grade IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L)</title>
        <description>The descriptive system comprises five dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels (5L): no problems (1) , slight problems (2), moderate problems (3), severe problems (4) and extreme problems (5).
Minimum score is 5 (no problems) and maximum score is 25 (extreme problems)
An overall health question is asked using a visual analogue scale(VAS) from 0-100 where 0 is bad health and 100 good health</description>
        <time_frame>From four week run-in period to last four weeks in the randomization period</time_frame>
        <population>Randomized population, Intention to Treat (ITT) In the active group 24 subjects had missing data, in the sham group 35 subjects had missing data at the end of the randomized period</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L)</title>
          <description>The descriptive system comprises five dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels (5L): no problems (1) , slight problems (2), moderate problems (3), severe problems (4) and extreme problems (5).
Minimum score is 5 (no problems) and maximum score is 25 (extreme problems)
An overall health question is asked using a visual analogue scale(VAS) from 0-100 where 0 is bad health and 100 good health</description>
          <population>Randomized population, Intention to Treat (ITT) In the active group 24 subjects had missing data, in the sham group 35 subjects had missing data at the end of the randomized period</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility run-in period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="1.10" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility randomized period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1.07" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Selfcare run-in period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Selfcare randomized period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1.02" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities run-in period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="1.23" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities randomized period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1.22" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/discomfort run-in period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="1.59" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/discomfort randomized period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/depression run-in period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/depression randomized period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="1.41" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual analogue scale )VAS) run-in period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="167"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.97" lower_limit="5" upper_limit="100"/>
                    <measurement group_id="O2" value="80.3" lower_limit="8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual analogue scale (VAS) randomized period</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.46" lower_limit="38" upper_limit="100"/>
                    <measurement group_id="O2" value="76.35" lower_limit="30" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Migraine Days in the Open Label Period (Adjusted ANCOVA)</title>
        <description>Change in number of migraine days (as reported in subject diary) during the 6 month open label period compared to the baseline run-in period.</description>
        <time_frame>The 6 month open-label period compared to the four week run-in period</time_frame>
        <population>Randomized population (Intent to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Migraine Days in the Open Label Period (Adjusted ANCOVA)</title>
          <description>Change in number of migraine days (as reported in subject diary) during the 6 month open label period compared to the baseline run-in period.</description>
          <population>Randomized population (Intent to treat)</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Migraine days run in period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="O2" value="7.9" lower_limit="3" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine days open label period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O2" value="5.7" lower_limit="0" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Adverse Effects were collected for all subjects for the duration of the study.</description>
        <time_frame>up to Week 36</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O3">
            <title>Not Randomized</title>
            <description>Subjects that were screen failures and were not randomized.</description>
          </group>
          <group group_id="O4">
            <title>Open Label</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Adverse Effects were collected for all subjects for the duration of the study.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events (non-serious)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Headache Days in the Open Label Period</title>
        <description>The mean change in number of headache days (as reported in the subject diary) during the open label period compared to the base-line run-in period</description>
        <time_frame>The 6 month open-label period compared to the four week run-in period</time_frame>
        <population>Randomized population (Intent to treat)</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore®-R</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
          <group group_id="O2">
            <title>gammaCore®-R Sham</title>
            <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Headache Days in the Open Label Period</title>
          <description>The mean change in number of headache days (as reported in the subject diary) during the open label period compared to the base-line run-in period</description>
          <population>Randomized population (Intent to treat)</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" lower_limit="-1.08" upper_limit="-0.02"/>
                    <measurement group_id="O2" value="-0.51" lower_limit="-1.02" upper_limit="-0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>40 weeks (run-in 4 weeks, double blind/randomized 12 weeks, open label 24 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>gammaCore®-R</title>
          <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
        </group>
        <group group_id="E2">
          <title>gammaCore®-R Sham</title>
          <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
gammaCore®-R Sham: Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
        </group>
        <group group_id="E3">
          <title>Not Randomised</title>
          <description>Subjects that were screen failures and were not randomized.</description>
        </group>
        <group group_id="E4">
          <title>Open Label</title>
          <description>Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>carrier BRCA2 gene, prophylactic surgery: adnex extirpation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Admitted because of suspecion of appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>obstructive syndrom with dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Surgery for removal cyste and twisted fallopian tube left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="118" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Conjunctival irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Eczema eyelids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Application site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Application site pustules</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="169"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="172"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E4" events="21" subjects_affected="18" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Q fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Splinter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tooth injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Aura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Phantom pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Status migrainosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dysphemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Acne cystic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Skin discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cyst removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dental implantation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Dental operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Oophorectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Papilloma excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Preventive surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Skin lesion excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Tooth repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="172"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Labile blood pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Affairs</name_or_title>
      <organization>electroCore INC</organization>
      <phone>+1 973 355 6683</phone>
      <email>clinical@electrocore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

